MedTrace Logo

Hepatic Xenetix-CT Perfusion

NCT01639703 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2017-07-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.

Conditions

Interventions

DRUG

Xenetix-CT perfusion imaging

Injection of 50 ml of Xenetix

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Hatem Alkadhi · Zurich University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Austria
  • Germany
  • South Korea
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639703 on ClinicalTrials.gov